GP trainer and palliative care lead Dr Nicolas Alexander advises on the key non-pain symptoms that patients experience during ...

Phase 1 healthy volunteer trial ongoing, complete SAD/MAD data expected in June 2025 KT-621 Phase 1b trial in atopic dermatitis (AD) patients expected to initiate in 2Q25 with data in 4Q25, followed ...

Asthma isn’t curable, but treatment can help. Consider talking with a family doctor first to learn more about ... such as chronic obstructive pulmonary disease (COPD), pneumonia, and emphysema.

Astrana Health, Inc. ( NASDAQ: ASTH) Q4 2024 Earnings Conference Call February 27, 2025 5:30 PM ET Brandon Sim - President & CEO Chan Basho - Chief Operating & Financial Officer ...

(NASDAQ: REGN) stock has gone relatively unnoticed from major headlines in 2024 as GLP-1 makers like Novo Nordisk A/S (NYSE: ...

The increasing prevalence of nontuberculous mycobacteria (NTM) infections worldwide poses significant public health challenges, underscored by high fatality ...

: The Holy See Press Office, in a statement on Saturday, March 1, morning said that Pope Francis slept well and spent the ...

Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...

The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...

The FDA has approved Tevimbra (tislelizumab) for use in combination with chemotherapy as first-line treatment for unresectable or metastatic, PD-L1-positive ESCC.

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

Several rare disease patient populations received their first-ever FDA-approved drug since Rare Disease Day last year, ...